Trimers, molecules and polarons in imbalanced atomic Fermi gases

We consider the ground state of a single "spin-down" impurity atom interacting attractively with a "spin-up" atomic Fermi gas. By constructing variational wave functions for polarons, molecules and trimers, we perform a detailed study of the transitions between each of these dressed bound states as a function of mass ratio $r=m_\uparrow/m_\downarrow$ and interaction strength. We find that the presence of a Fermi sea enhances the stability of the $p$-wave trimer, which can be viewed as a Fulde-Ferrell-Larkin-Ovchinnikov (FFLO) molecule that has bound an additional majority atom. For sufficiently large $r$, we find that the transitions lie outside the region of phase separation in imbalanced Fermi gases and should thus be observable in experiment, unlike the well-studied equal-mass case.Comment: 5 pages, 2 figure

Enlarging and cooling the N\'eel state in an optical lattice

We propose an experimental scheme to favor both the realization and the detection of the N\'eel state in a two-component gas of ultracold fermions in a three-dimensional simple-cubic optical lattice. By adding three compensating Gaussian laser beams to the standard three pairs of retroreflected lattice beams, and adjusting the relative waists and intensities of the beams, one can significantly enhance the size of the N\'eel state in the trap, thus increasing the signal of optical Bragg scattering. Furthermore, the additional beams provide for adjustment of the local chemical potential and the possibility to evaporatively cool the gas while in the lattice. Our proposals are relevant to other attempts to realize many-body quantum phases in optical lattices.Comment: 8 pages, 10 figures (significantly revised text and figures

Phase separation and collapse in Bose-Fermi mixtures with a Feshbach resonance

We consider a mixture of single-component bosonic and fermionic atoms with an interspecies interaction that is varied using a Feshbach resonance. By performing a mean-field analysis of a two-channel model, which describes both narrow and broad Feshbach resonances, we find an unexpectedly rich phase diagram at zero temperature: Bose-condensed and non-Bose-condensed phases form a variety of phase-separated states that are accompanied by both critical and tricritical points. We discuss the implications of our results for the experimentally observed collapse of Bose-Fermi mixtures on the attractive side of the Feshbach resonance, and we make predictions for future experiments on Bose-Fermi mixtures close to a Feshbach resonance.Comment: 7 pages, 3 figures. Extended versio

Quantum Flutter: Signatures and Robustness

We investigate the motion of an impurity particle injected with finite velocity into an interacting one-dimensional quantum gas. Using large-scale numerical simulations based on matrix product states, we observe and quantitatively analyze long-lived oscillations of the impurity momentum around a nonzero saturation value, called quantum flutter. We show that the quantum flutter frequency is equal to the energy difference between two branches of collective excitations of the model. We propose an explanation of the finite saturation momentum of the impurity based on the properties of the edge of the excitation spectrum. Our results indicate that quantum flutter exists away from integrability and provide parameter regions in which it could be observed in experiments with ultracold atoms using currently available technology.Physic

Quantum flutter of supersonic particles in one-dimensional quantum liquids

The non-equilibrium dynamics of strongly correlated many-body systems exhibits some of the most puzzling phenomena and challenging problems in condensed matter physics. Here we report on essentially exact results on the time evolution of an impurity injected at a finite velocity into a one-dimensional quantum liquid. We provide the first quantitative study of the formation of the correlation hole around a particle in a strongly coupled many-body quantum system, and find that the resulting correlated state does not come to a complete stop but reaches a steady state which propagates at a finite velocity. We also uncover a novel physical phenomenon when the impurity is injected at supersonic velocities: the correlation hole undergoes long-lived coherent oscillations around the impurity, an effect we call quantum flutter. We provide a detailed understanding and an intuitive physical picture of these intriguing discoveries, and propose an experimental setup where this physics can be realized and probed directly.Comment: 13 pages, 9 figure

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity- purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity- purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains